0000876661-23-000463.txt : 20230601
0000876661-23-000463.hdr.sgml : 20230601
20230601113759
ACCESSION NUMBER: 0000876661-23-000463
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20230601
DATE AS OF CHANGE: 20230601
EFFECTIVENESS DATE: 20230601
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 23983581
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NEW YORK STOCK EXCHANGE LLC
CENTRAL INDEX KEY: 0000876661
IRS NUMBER: 000000000
STATE OF INCORPORATION: NY
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-2060
MAIL ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NEW YORK STOCK EXCHANGE INC
DATE OF NAME CHANGE: 19910628
25-NSE
1
primary_doc.xml
X0203
0000876661
NEW YORK STOCK EXCHANGE LLC
0000885725
BOSTON SCIENTIFIC CORP
001-11083
300 Boston Scientific Way
Marlborough
MA
MASSACHUSETTS
01752
(508) 683-4000
5.50% Mandatory Convertible Preferred Stock, Series A
17 CFR 240.12d2-2(a)(3)
Victoria Paper
Manager, Market Watch and Proxy Compliance
2023-06-01
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on June 12, 2023, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on June 01, 2023 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
Each share of 5.50% Mandatory Convertible Preferred Stock, Series A will be converted into 2.3834 shares of the common stock of Boston Scientific Corporation.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on June 01, 2023.